Network meta-analysis of pneumonitis and interstitial lung disease associated with antibody-drug conjugates in the treatment of breast cancer
- VernacularTitle:抗体偶联药物治疗乳腺癌后致肺炎和间质性肺病的网状Meta分析
- Author:
Xiaohan WANG
1
;
Wei CHEN
2
;
Fang YANG
3
;
Keming CAO
4
;
Jingxin WANG
4
;
Wenxin XUE
2
Author Information
1. School of Pharmacy，North China University of Science and Technology，Tangshan 063210，China;Dept. of Pharmacy，Emergency General Hospital，Beijing 100028，China
2. Dept. of Pharmacy，Emergency General Hospital，Beijing 100028，China
3. Dept. of General Outpatient，East Campus，Emergency General Hospital，Beijing 100016，China
4. School of Pharmacy，North China University of Science and Technology，Tangshan 063210，China
- Publication Type:Journal Article
- Keywords:
breast cancer;
antibody-drug conjugates
- From:
China Pharmacy
2026;37(10):1370-1375
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To compare the risk of pneumonitis and interstitial lung disease （ILD） associated with different antibody-drug conjugates （ADC） in the treatment of breast cancer. METHODS CNKI， VIP， PubMed， Embase and other Chinese and English databases， and ClinicalTrials.gov were searched from the inception to June 15， 2025. Randomized controlled trials （RCT） about pneumonitis and ILD associated with ADC （T-DM1， T-DXd， SG， Dato-DXd， SHR-A1811，ARX788， and T-Duo） in the treatment of breast cancer were included. After literature screening， data extraction， and quality assessment， a network meta-analysis was conducted using Stata 17.0 software， and the surface under the cumulative ranking curve（SUCRA） of all interventions were ranked. RESULTS A total of 19 RCTs involving 10 556 patients were included. The overall incidence of pneumonitis with ARX788 and T-DXd was significantly higher than that with T-DM1， T-DM1 plus TPC（T-DM1combined with pertuzumab or atezolizumab）， TPC（treatment of primary care）， and SG （ P ＜0.05）， for grade 1-2 pneumonitis， ARX788 and T-DXd showed significantly higher incidence than T-DM1， T-DM1 plus TPC， and TPC （ P ＜0.05）. For both indicators， ARX788 and T-Duo were ranked as the top two by SUCRA. For the incidence of grade ≥3 pneumonitis， T-DXd and T-DM1 were significantly higher than SG （ P ＜0.05）， T-Duo and Dato-DXd were ranked as the top two by SUCRA. For overall incidence of ILD， ARX788 was significantly higher than T-DM1， SHR-A1811， TPC， and SG （ P ＜0.05）， for the incidence of grade 1-2 ILD， ARX788 was significantly higher than T-DM1， SHR-A1811， and TPC （ P ＜0.05）， for the incidence of grade ≥3 ILD， ARX788 was significantly higher than TPC （ P ＜0.05）. For three indicators above， ARX788 and T-DXd combined with pertuzumab were ranked as the top two by SUCRA. CONCLUSIONS Compared with other ADCs， ARX788 and T-Duo are associated with a higher risk of pneumonitis and ILD in patients with breast cancer.
